PCI Biotech Holding ASA: PCI Biotech fourth quarter and preliminary full year 2020 results Highlights Chem *The first Asian patient was enrolled in the RELEASE study in South Korea in October, less than three months after opening of the first study site in Asia. All the nine planned study sites in South Korea and Taiwan have been opened, with initial good screening activity *Several initiatives have been implemented in the RELEASE study to recoup long-term recruitment projections. Besides going into Asia, the most important initiatives are the protocol amendment made to expand the eligible patient population and the addition of new clinical sites